Qiagen Reports 26 Percent Jump in Q1 Revenues | GenomeWeb

NEW YORK, May 7 – Nucleic acid handling company Qiagen said Monday its first quarter revenues rose 26 percent to $63.1 million, compared with $50.2 million in the year ago quarter.

Total operating expenses increased 27 percent to $34.3 million, compared with $27 million in the year ago period, as research and development, sales and marketing, and general and administrative costs rose across the board. Qiagen of Venlo, The Netherlands, also posted expenses totaling $3 million stemming from the acquisition of Japan’s Sawady group of companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."